Ligand Pharmaceuticals Incorporated is reaffirming its 2024 financial guidance. The Company expects 2024 royalties ranging from $90 million to $95 million, sales of Captisol to range from $25 million to $27 million, and contract revenue ranging from $15 million to $20 million. These revenue components result in total revenue forecast of $130 million to $142 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
81.36 USD | -1.23% | -4.34% | +13.92% |
May. 13 | Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing | MT |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.92% | 1.46B | |
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B |
- Stock Market
- Equities
- LGND Stock
- News Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024